Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244502 | 0.82 | ROCK1 (0.40) | CYP1A2CYP3A4ALDH1A1CYP2D6MAPT | |
| SCHEMBL21017395 | 0.80 | ALDH1A1 (0.37) | CYP1A2CYP3A4ALDH1A1CYP2D6MAPT | |
| SCHEMBL26551523 | 0.79 | TLR8 (0.44) | CYP1A2CYP3A4ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL26573670 | 0.79 | FLT3 (0.39) | CYP1A2CYP3A4ALDH1A1CYP2D6MAPT | |
| SCHEMBL26548758 | 0.76 | MAP4K1 (0.37) | CYP1A2CYP3A4ALDH1A1CYP2D6MAPT | |
| SCHEMBL13950483 | 0.76 | RAB9A (0.59) | CYP1A2CYP3A4ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL30421381 | 0.76 | CYP1A2 (0.49) | CYP1A2ALDH1A1LMNA | |
| SCHEMBL12501346 | 0.76 | HRH3 (0.44) | CYP1A2CYP3A4ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL23768151 | 0.74 | PLK1 (0.38) | ALDH1A1MAPTMEN1NPC1LMNA | |
| SCHEMBL22971224 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023279280-A1 | N-(ARYLSULFONYL)-INDOLE-2-CARBOXAMIDE FBPASE INHIBITOR AND USE THEREOF | 中国医学科学院药物研究所 | 2023-01-12 | — | — | WO | disclosed |
| US-8178671-B2 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102007115-A | Pyrimidylmethyl sulfonamide compounds | BASF SE | 2011-04-06 | — | — | CN | disclosed |
| US-20110077153-A1 | Substituted Heteroarylmethyl Sulfonamides | BASF SE (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2252606-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009141291-A1 | SUBSTITUTED HETEROARYLMETHYL SULFONAMIDES | BASF SE (DE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009101078-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009101079-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7122542-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | CYP1A2 1939/4885CYP3A4 3017/4885ALDH1A1 3877/4885 |
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | CYP1A2 172/4885CYP3A4 484/4885ALDH1A1 1071/4885 |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | CYP1A2 1939/4885CYP3A4 3017/4885ALDH1A1 3877/4885 |
| US-20110077153-A1 | Substituted Heteroarylmethyl Sulfonamides | ARSA, STS, CCNY | CYP1A2 43/4885CYP3A4 186/4885ALDH1A1 1698/4885 |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | SSB, TYMS, TPMT | CYP1A2 1939/4885CYP3A4 3017/4885ALDH1A1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.